A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity (NDO).

Trial Profile

A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity (NDO).

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Detrusor instability
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma BV
  • Most Recent Events

    • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Apr 2012 Additional trial locations (United Kingdom, USA) identified as reported by EudraCT.
    • 24 Feb 2012 Additional trial locations added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top